等待開盤 03-26 09:30:00 美东时间
+0.440
+1.56%
TradingKey - Investing in SpaceX concept stocks is essentially a move to capture the certain growth of the commercial aerospace wave and share in the industrial dividends of disruptive technological innovation.
03-25 13:24
Turkey - Factors to Watch on March 25 ISTANBUL, March 25 (Reuters) - Here are news, reports and events that may affect Turkish financial markets on Wednesday. The lira TRYTOM=D3 was quoted at 44.3575 against the U.S. dollar at 0427 GMT, compared with a close of 44.34 on Tuesday. The BIST 100 index c
03-25 13:10
Assembly Biosciences Inc ($ASMB) announced an update on their ongoing clinical ...
03-24 00:30
Genasys appoints Bill Dodd as board chairman Genasys appointed Bill Dodd as chairman of its board following the retirement of Richard Osgood. Dodd has served on the board since May 2024 and previously served in the California State Senate from December 2016 to December 2024. His earlier public servi
03-23 21:02
UPDATE 2-BOK signals hawkish turn as South Korea appoints anti-debt expert Shin Recasts with comments from government Shin Hyun-song appointed as new BOK governor, signaling hawkish policy shift Shin known for predicting 2008 crisis, focuses on excessive leveraging risks BOK likely to keep interest
03-22 16:04
Gray Media and the Atlanta Braves have announced a simulcast of the Braves' 2026 home opener against the Kansas City Royals on March 27. The game will air on BravesVision and Gray Media’s local stations, bringing the event to fans across the Southeast. Pre-game festivities include a 60th anniversary celebration with player walk, legendary appearances, and a ceremonial first pitch. The partnership ensures wider accessibility for fans to enjoy the ...
03-20 16:41
Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $(0.65) by 300 percent. This is a 182.8 percent increase over losses of $(1.57) per share
03-20 04:38
Anduril Industries is set to launch its Arsenal-1 weapons manufacturing facility, with assembly lines expected to come online within weeks.
03-19 21:57
Assembly Biosciences reported the authorization of their helicase-primase inhibitor program for recurrent genital herpes to Gilead, including ABI-5366 and ABI-1179, following positive Phase 1b interim data. The collaboration with Gilead resulted in a net $35 million option fee. The company also initiated a Phase 2 clinical study for ABI-6250, an oral small-molecule entry inhibitor for chronic hepatitis delta virus, expected to begin by the end of...
03-19 20:05